The shortage of drugs active against meticillin-resistant Staphylococcus aureus (MRSA) is a growing clinical problem. In vitro studies indicate that the phenothiazine thioridazine (TZ) might enhance the activity of the b-lactam antibiotic dicloxacillin (DCX) to a level where MRSA is killed, but experiments in simple animal models have not been performed. In the present study, we introduced Caenorhabditis elegans infected by S. aureus as an in vivo model to test the effect of TZ as a helper drug in combination with DCX. Because TZ is an anthelmintic, initial experiments were carried out to define the thresholds of toxicity, determined by larval development, and induction of stress-response markers. No measurable effects were seen at concentrations of less than 64 mg TZ l "1 . Seven different MRSA strains were tested for pathogenicity against C. elegans, and the most virulent strain (ATCC 33591) was selected for further analyses. In a final experiment, full-grown C. elegans were exposed to the test strain for 3 days and subsequently treated with 8 mg DCX l "1 and 8 mg TZ l "1 for 2 days. This resulted in a 14-fold reduction in the intestinal MRSA load as compared with untreated controls. Each drug alone resulted in a two-to threefold reduction in MRSA load. In conclusion, C. elegans can be used as a simple model to test synergy between DCX and TZ against MRSA. The previously demonstrated in vitro synergy can be reproduced in vivo.
INTRODUCTION
The treatment of meticillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly problematic worldwide. Many strains are multi-drug resistant and there is a shortage of active drugs because of slow progress in developing new antibiotics (Fischbach & Walsh, 2009) . Therefore, there is an urgent need for new strategies with which to manage MRSA.
MRSA is resistant to dicloxacillin (DCX) and other penicillinase-resistant penicillins, which are the drugs of choice for the treatment of meticillin-susceptible S. aureus (MSSA). We have previously shown that the neuroleptic drug thioridazine (TZ) acts in synergy with DCX to an extent that restores the susceptibility of MRSA to DCX and increases the susceptibility of MSSA to DCX in vitro (Klitgaard et al., 2008; Poulsen et al., 2013) . Furthermore, we have analysed the molecular mechanisms underlying the synergy between TZ and DCX (Bonde et al., 2011; Klitgaard et al., 2008; Thorsing et al., 2013) . Most importantly, TZ was shown to affect the cell wall biosynthesis pathway by interfering with the formation of the pentaglycine bridge of peptidoglycan precursors, resulting in enhanced sensitivity to DCX (Thorsing et al., 2013) . From a clinical point of view, the combination of TZ and DCX looks promising. Before this combination can be tested in a clinical setting, however, animal experiments are needed.
The nematode Caenorhabditis elegans has been established as a host model for S. aureus pathogenesis, in which nematodes fed S. aureus die over the course of days as a result of an accumulation of bacteria within the digestive tract (Sifri et al., 2003) . C. elegans is a genetically tractable multicellular organism that has been applied to the study of microbial pathogenesis and host innate immunity, and been used in drug discovery and development (Ewbank & Zugasti, 2011; Simonsen et al., 2012) . When S. aureus infects C. elegans, the nematode mounts an innate immune response involving activation of specific signalling pathways leading to the production and release of defence molecules. The response of C. elegans is mainly microbicidal and detoxifying (Irazoqui et al., 2010) . Thus, C. elegans is a good host organism in which to test treatment strategies, including the current drug combination.
In this study, we established an animal treatment model with C. elegans to study the synergistic effects of DCX and TZ. When establishing the model, we had to take into account the fact that TZ, like other phenothiazines, acts as an anthelmintic with inhibitory effects on the development of C. elegans eggs and larvae (Patel & Campbell, 1998) . Using this model, we show that combined treatment with TZ and DCX reduces the MRSA load in nematodes to a higher degree than monotherapy with each drug, at concentrations where TZ itself does not inhibit the development of nematode eggs or larvae.
METHODS
Nematodes, bacterial strains and growth media. The standard food source of C. elegans, Escherichia coli strain OP50, was grown with shaking in LB medium at 37 uC. Selected MRSA strains (Table 1) from Statens Serum Institut and Odense University Hospital, as well as reference strain MSSA Olsen (Aarhus University), were grown at 37 uC without agitation in BBL Trypticase soy broth (TSB) to enhance the virulence of the bacteria and kept in aliquots at 280 uC in beef bouillon with 10 % glycerol (Statens Serum Institut).
C. elegans strains SS104 [glp-4(bn2)I], wild-type N2, SJ4005 [zcIs4 (hsp-4 : : GFP) V], CL2070 [dvls70 (hsp-16.2 : : gfp; rol-6{su1006})] and TJ356 [zIs356 (Pdaf-16 : : daf-16a/b-gfp; rol-6)] were obtained from the Caenorhabditis Genetics Center. The SS104 strain was maintained at 15 uC and the N2, SJ4005, CL2070 and TJ356 strains at 20 uC on nematode growth medium (NGM) plates spotted with the E. coli strain OP50 using established procedures (Brenner, 1974) .
For seeding of OP50, the bacteria were cultured in LB O/N at 37 uC before being spotted onto the NGM plates. Three drops of the overnight (O/N) culture were then spotted onto the NGM plates and the bacteria were allowed to continue growing for 1-2 days at room temperature before nematodes were added to the plates. For seeding of S. aureus strains, the bacteria were cultured in TSB O/N at 37 uC before 1 drop was spotted onto the NGM plates. The bacteria were allowed to grow on O/N at 37 uC and cooled to room temperature before nematodes were added to the plates.
Synchronization of C. elegans. Eggs were collected, transferred to NGM plates seeded with OP50 and grown to larvae stage L4. The temperature-sensitive SS104 mutants are sterile at 25 uC. Therefore, to avoid confounding effects of the progeny in the bacterial expelling assay, the glp-4 mutants were cultured at 25 uC. The N2, SJ4005, CL2070 and TJ356 strains were grown at 20 uC.
Effect of TZ and DCX on the nematode stress response. Eggs or synchronized L4 worms (N2, SJ4005, CL2070 or TJ356) were Treatment of MRSA in C. elegans by combined therapy transferred to OP50 seeded NGM plates with TZ (Sigma Aldrich) and DCX (Bristol-Myers Squibb) alone or in combination (final concentrations of 8-64 mg l 21 in plates). Eggs or worms without treatment but exposed to sterile and double-distilled water added to the NGM were included as controls. Worms were collected after 1 day (from L4 larvae) or 3 days (from eggs) of treatment and analysed by fluorescence microscopy (Leica DMI3000 B microscope equipped with an Olympus DP72 camera). The intensity of green fluorescence and the size of the worms were measured using ImageJ software (http:// imagej.nih.gov/ij). Experiments were repeated twice in duplicate and Student's t-test was applied for statistical analysis.
C. elegans survival assay. TSB agar plates were spotted with 1 drop of MRSA or MSSA and incubated for 24 h at 37 uC, before being cooled to room temperature. Fifty synchronized L4 glp-4(bn2) larvae were transferred to each plate. Drugs were added to the plates in final concentrations and the plates were left to solidify. Plates were incubated at 25 uC and scored daily for live and dead worms. Worms were considered dead and were removed when they did not respond to gentle prodding with a platinum wire. Survival data from three plates were compiled in order to produce Kaplan-Meier survival curves. Statistical analysis was performed using the log-rank test with GraphPad Prism 4.03 software, and a P-value of ,0.05 was considered statistically significant.
Nematode colonization measurement. Synchronized L4 glp-4(bn2) mutants were transferred to TSB agar plates spotted with MRSA strain ATCC 33591 and incubated at 25 uC for 3 days to establish infection. To initiate treatment, the infected worms were washed off the plates with M9 buffer, washed three times in M9 buffer and transferred to OP50 seeded NGM plates with TZ and DCX alone or in combination (final concentration of 8 mg l 21 in plates). Worms without treatment were included as controls. The bacterial load in the nematode intestine was determined as described previously (Moy et al., 2006) . Ten nematodes were pooled and transferred to a microcentrifuge tube with 1 ml M9 buffer [3 g KH 2 PO 4 l 21 , 6 g Na 2 HPO 4 l 21 , 5 g NaCl l
21
, 1 ml (1 M MgSO 4 ) l
] containing 1 mM sodium azide to inhibit expulsion of bacteria from the nematode intestine. The number of c.f.u. per nematode was determined as described previously (Simonsen et al., 2011) . The experiment was repeated twice with similar results and representative results are presented in Fig. 5 .
RESULTS AND DISCUSSION

Effect of TZ and DCX on the nematode immune response
Since the 1930s, phenothiazines have been used in veterinary treatment as anthelmintics (Ohlow & Moosmann, 2011; Swales, 1936) . In order to establish nematodes as a treatment model for the combination of a phenothiazine and antibiotic, the applied concentration of the phenothiazine must consequently be below the concentration that affects the nematode state. Taking this into account, it might be considered difficult to use C. elegans as a host model for treatment with TZ since the compound could act as a stressor, upregulating stress defence systems (hormetic response) or even killing the nematodes.
The inhibitory effect of the phenothiazine chlorpromazine in the parasitic nematode Haemonchus contortus and the free-living nematode C. elegans has been shown previously (Patel & Campbell, 1998) . In the study by Patel & Campell, the larvae that hatched in high concentrations (100 mg l 21 ) of chlorpromazine were killed, while those that hatched in low concentrations (6.25 mg l 21 ) were not. Consequently, we tested the toxicity of the phenothiazine TZ towards C. elegans at concentrations that were antimicrobial relevant (0, 16, 32, 64 and 128 mg TZ l 21 ) by observing the survival of the worms (Fig. 1a) . Statistical analysis using a log-rank test in GraphPad showed no difference in survival when the nematodes were treated with concentrations below 64 mg TZ l 21 compared with untreated nematodes. However, the survival of nematodes treated with 128 mg TZ l 21 was significantly decreased compared with untreated nematodes (P50.027). TZ showed no inhibition of hatching at the tested concentrations.
Although the C. elegans worms survived exposure to 64 mg TZ l
21
, this dose could potentially still initiate a stress response in the nematodes that would complicate the interpretation of treatment experiments. Consequently, we tested the effect of TZ (32 and 64 mg l 21 ) on development. The concentrations of both TZ and DCX (32 and 64 mg l
) were chosen based on MICs (Table 1 ) and the concentrations previously used for in vitro viability assays to test for synergy of the two drugs (Klitgaard et al., 2008; Poulsen et al., 2013) . Because DCX was expected to affect the bacteria only, we did not expect it to stress the nematodes, but we included DCX in our analysis as a control. The C. elegans worms were exposed to TZ or DCX alone or in combination under a microscope and compared with control worms exposed to sterile water. Nematodes of the wild-type N2 strain that were exposed from eggs to TZ at high concentrations (64 mg l
) exhibited developmental arrest (Fig. 1b, Table 2 ). The worms were significantly smaller in size and had arrested larval development compared with those not exposed to any drugs. At lower concentrations, the development of the nematodes was unaffected.
To examine the possible induction of stress-response markers in C. elegans by the two drugs, we examined the small heat-shock protein (HSP)-16, which is induced by various types of stress (Olsen et al., 2006) , the endoplasmic reticulum (ER) stress-response marker HSP-4 (homologue of the human ER chaperone BiP) (Urano et al., 2002) and the FoxO transcription factor daf-16. The C. elegans strains CL2070, SJ4005 and TJ356 are GFP-fusion mutants representing hsp-16, hsp-4 and daf-16, respectively (Henderson & Johnson, 2001; Lin et al., 1997; Ogg et al., 1997; Olsen et al., 2006) . As the worm experiences various kinds of stressors, introducing protein misfolding, the HSP-16 : : GFP and HSP-4 : : GFP proteins in CL2070 and SJ4005 are upregulated and green fluorescence will appear. The DAF-16 : : GFP protein, on the other hand, is translocated to the nucleus during stress and reduced insulin signalling. The ratio between the mean value of the fluorescence of worms exposed to drugs and controls (no drugs) was determined.
We saw no significant upregulation of the ER stressresponse marker hsp-4 (Fig. 2a, b) and no translocation of DAF-16 to the nucleus (Fig. 2c) when the nematodes were exposed to TZ and DCX from eggs. Using the CL2070 hsp-16 : : GFP transcriptional reporter, we also did not observe any increases in hsp-16 transcription (data not shown). The same was observed when the nematodes were exposed from the L4 stage (Fig. 3a-c) . DCX alone did not have an effect on the hatching and growth of the nematodes (data not shown). At neither stage did the worms appear stressed by the chosen concentrations of TZ and DCX. HSP-4 expression is always observed in the spermatheca, even if the worms are not experiencing ER stress (Urano et al., 2002) . The results indicate that neither TZ nor DCX, either alone or in combination, in the concentrations chosen was stressful to the nematodes. This was the case regardless of whether the nematodes were exposed to the drugs from eggs or from larval stages. Therefore, we conclude that treatment with doses of TZ or DCX below 64 mg l 21 does not cause an unwanted stress response in C. elegans nematodes.
Infection of C. elegans with MRSA strains of different pathogenicity
Although our analysis of development and stress-response induction suggests that TZ and DCX doses of up to 32 mg l 21 can be used without affecting the worms, we decided to use a much lower dose (8 mg l
21
) for the treatment experiments to rule out any non-bacterial effects of TZ and DCX on the host model.
We tested the pathogenicity of seven selected MRSA strains against the non-pathogenic MSSA strain Olsen on C. elegans (Table 1) . MRSA isolates are divided into different types according to a staphylococcal chromosome cassette carrying the resistance gene mecA (SCCmec), among others. Strains were selected based on different SCCmec types and different responses to the synergistic effect of combined treatment with TZ and DCX observed in previous experiments (Poulsen et al., 2013) . Synchronized C. elegans glp-4(bn2) mutants were fed on the eight S. aureus strains and live worms were scored every day. As expected, the MRSA strains were more pathogenic to C. elegans and killed the worms faster than MSSA Olsen (Fig. 4a) . Of the MRSA strains tested, the most pathogenic strain seemed to be ATCC 33591. A log-rank test comparing median survival between the different C. elegans strains revealed that the S. aureus strains tested in this study could be divided into four virulence or pathogenic categories: the first containing MSSA Olsen; the second containing the less virulent MRSA strains 51642, 110605, 52944 and 55508; the third containing the slightly more virulent MRSA strains 99190 and USA300; and the last containing the most virulent MRSA strain Treatment of MRSA in C. elegans by combined therapy ATCC 33591 (Fig. 4b) . Differences in pathogenicity between healthcare-associated (HA)-MRSA and community-associated (CA)-MRSA have been addressed previously. We were not able to see any differences regarding the SCCmec types, as the two HA-MRSA strains were located at each end of the pathogenicity scale (51642 and ATCC 33591). Two groups have demonstrated previously that CA-MRSA strains are more pathogenic than HA-MRSA strains in the C. elegans model (Day et al., 2012; Wu et al., 2010) . However, no common virulence gene pattern or specific genes were found to be associated with the pathogenicity of nematocidal strains in the C. elegans model. We were not able to verify the observation of CA-MRSA being more pathogenic to nematodes with the low number of S. aureus strains tested in the current study. In fact, the most pathogenic of our MRSA strains was ATCC 33591, described as belonging to the HA strains. Day et al. (2012) previously demonstrated that some strains of HA-MRSA are as virulent to nematodes as prototypic strains of CA-MRSA, a finding that seems consistent with our findings. Based on the lifespan experiments performed in this study, we chose to use the strain ATCC 33591 for infection of C. elegans in our nematode host treatment model.
Combination therapy with TZ and DCX clears MRSA from the nematode gut
The established nematode model was used to study combined treatment with TZ and DCX. The experiments were performed with as low concentrations of TZ and DCX as possible for two reasons: first, to reduce the anthelmintic effect of TZ on the nematodes; and second, to demonstrate that combined treatment is more efficient than monotherapy. The concentrations of 8 mg TZ l 21 and 8 mg DCX l 21 that were used in the current study are well below the concentrations of 64 mg TZ l 21 and 16 mg DCX l 21 that were used for in vitro synergy experiments, in which this combination killed the ATCC 33591 strain (Klitgaard et al., 2008) .
In the nematode model, we tested whether the combination of TZ and DCX could clear an established infection from the nematode intestine more efficiently than no treatment or treatment with either TZ or DCX alone. We measured the bacterial load in the intestines of nematodes that were infected for 3 days with MRSA strain ATCC 33591, and shifted to feed on OP50 while being treated with TZ and/or DCX. During the experiment, which lasted for a total of 5 days, there was no difference in nematode survival (data not shown). The starting bacterial load at day 0 was 2.3610 4 c.f.u. ml
21
. After 2 days, the number of bacteria in untreated nematodes increased to 1.1610 5 c.f.u. ml
, indicating that the MRSA strain was, as expected, capable of multiplying inside the nematode intestine. At day 2, the bacterial load was reduced to 7.6610 3 c.f.u. ml 21 in the nematodes treated with DCX combined with TZ compared with untreated worms. This indicates a bacteriostatic effect of the combined drugs compared with untreated nematodes within the time frame of the experiment. At day 2, combined treatment was associated with a 14-fold reduction in the number of surviving S. aureus versus no treatment (ratio 0.07 versus 1.00, respectively) (Fig. 5) . In comparison, TZ and DCX alone achieved two-and threefold reductions, respectively. It was not technically possible to follow the experiment for a longer period because the activity of TZ decreases over time due to natural degradation (Eap et al., 1993) .
The results indicate that combined treatment with TZ and DCX is able to reduce the MRSA load in C. elegans nematodes more efficiently than monotherapy with either drug alone, and thus seems effective not only in vitro but also in vivo in a simple model organism. This study on the synergistic effect of combined treatment with the phenothiazine TZ and the b-lactam antibiotic DCX confirms previous results from liquid cultured media (Klitgaard et al. 2008; Poulsen et al. 2013) . The observation of synergy is an important first step towards a possible clinical application. It could reduce antibiotic doses in future treatment regimens, and possibly slow the development of resistance in S. aureus. The next step is to test the combined treatment in more complex animal models. Treatment of MRSA in C. elegans by combined therapy
